- Introduction
- HIV-infected pregnant women without prior antiretroviral therapy
- HIV-infected pregnant women already receiving antiretroviral therapy
- HIV-infected women in labor who have had no prior therapy
- Infants born to mothers who have received no antiretroviral therapy during pregnancy or labor
- Monitoring
- United Kingdom guidelines
- United States guidelines
HIV-infected women in labor who have had no prior therapy
Since many cases of transmission occur near to or during birth, AZT is recommended during labor and for the new-born child. Several regimens could be recommended:
- (a) a single dose of nevirapine at the onset of labour and a single dose of nevirapine for the newborn at age 48 hours
- (b)oral AZT/3TC during labour and one week of oral AZT/3TC for the newborn
- (c)intravenous AZT for the mother during delivery and 6 weeks of AZT for the newborn
- (a) and (c) together
After delivery, the woman's health should be assessed to determine whether antiretroviral therapy is advisable for her own health.
latest aidsmap news
- High rate of death amongst patients with HIV diagnosed late
- CD4 cell count increases sustained up to five years in developing-world treatment programmes
- Raltegravir may have role in PEP if exposure involves drug-resistant HIV
- Excellent outcomes from five years of antiretroviral use in Botswana
- Study explores verbal and non-verbal communication in unprotected sex between men
- IL-2 provides quick ‘AIDS rescue’, but effect does not always last
- Once-a-day etravirine should work as first-line treatment
- Second-line combinations fail twice as often as first-line ones in the first year
- If you can't switch, better to stay on failing treatment than stop it, studies show
- Non-nucleoside resistance is efficiently transmitted within infection ‘clusters’